TAS-102

trifluridine/tipiracil · Taiho Oncology, Inc.

Drug timelines are a Plus or Pro feature.

45 regulatory and trial events tracked for TAS-102, covering 2018-08-07 to 2026-08-26. Get the full timeline:

Most recent: Clinical Trial Results: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer [Phase 3]

See pricing